A Phase 3 interventional study of Hydrochlorothiazide 50mg Tablet and Placebo Tablet in Pre-Eclampsia, Gestational Hypertension and Superimposed Pre-Eclampsia, sponsored by The University of Texas Medical Branch, Galveston. Terminated at 2 sites in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by The University of Texas Medical Branch, Galveston · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 229 studies in Pre-Eclampsia with a site in United States — 61 open to participants now, 77 under way, 6 of them phase 3. Pre-Eclampsia · United States.
Among the 229 studies in Pre-Eclampsia with a site in United States, this one is the 18th largest by enrollment of the 160 interventional ones that give a count, is one of 15 that started in 2017, is one of 12 in phase 3, and was the 88th registered.
917 studies on the registry are indexed under Pre-Eclampsia; 244 are open to participants now.
Browse Pre-Eclampsia studies →61 of the 229 studies in Pre-Eclampsia with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–50 · Women only
University of California, Irvine · Sites in United States
Ages 18+ · Women only
University of Alabama at Birmingham · Sites in United States
Ages 16–56 · Women only
Texas Southern University · Sites in United States
Ages 18–45 · Women only
Medicines360 · Sites in United States
Ages 18–99 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 162 Pre-Eclampsia studies recruiting now, 81 (50%) set no upper age limit and 80 (49%) stop at 75 or younger; 18 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
229 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 24 · Phase 3 15 · Phase 4 31
First in 2000; this study’s year is marked. 15 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 453 is above the median of 110 across 481 interventional studies indexed under Pre-Eclampsia.
Median enrollment 88 across the 160 interventional studies, 125 across the 69 observational. Of the 126 that completed or were terminated, 54 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 229 have an industry lead sponsor. The 10 most frequent:
The University of Texas Medical Branch, Galveston is the lead sponsor of 257 studies on the registry; 37 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
The University of Texas Medical Branch, Galveston has 3 studies filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
27 of the studies in Pre-Eclampsia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07222852Phase 3Women and Infants Hospital of Rhode IslandCardiovascular Protection After Preeclampsia With Enalapril | 2027-10-15 |
| NCT07293728Oregon Health and Science UniversityA Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia | 2026-12 |
| NCT07356518Wake Forest University Health SciencesTelehealth and Remote Blood Pressure | 2026-12 |
| NCT05676476University of Alabama at BirminghamThe ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy. | 2026-12 |
| NCT05924971MemorialCare Health SystemAspirin for Postpartum Patients With Preeclampsia | 2026-12 |
Add all 27 to your calendar (.ics) → With an account.
Among the 229 studies in Pre-Eclampsia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Postpartum prophylactic HCTZ administration for prevention and relapse of preeclampsia or gestational hypertension.
To evaluate effectiveness of hydrochlorothiazide prophylaxis on prophylaxis, prevention and relapse of preeclampsia or gestational hypertension on readmission rates, need for additional antihypertensive therapy and number of triage visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of gestational hypertension* or preeclampsia\^ at any time during pregnancy, labor or postpartum.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.
Drug: Hydrochlorothiazide 50mg Tablet
Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for fourteen days postpartum
Drug: Placebo Tablet
Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.
Also known as: HydroDIURIL, Microzide, Esidrix, Oretic
Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum
Also known as: sugar pill
Number of Participants Required Re-Admission or Triage Visit
Any participants who had a visit to the hospital during the 1-6 weeks postpartum.
Time frame: 1-6 weeks postpartum
Number of Participants That Need Additional Antihypertensive Therapy
Number of participants requiring additional antihypertensive agents in 1-6 weeks postpartum window
Time frame: 1-6 weeks postpartum
Length of Hospital Stay
Days that participants required to be in-house in the postpartum period
Time frame: 1-6 weeks postpartum
Total Additional Doses of Anti-hypertensive Therapy
Number of participants that receive one additional doses in the 1-6 weeks postpartum
Time frame: 1-6 weeks postpartum
Elevation of Blood Pressure >150/90
Number of participants that have a blood pressure greater than 150/90 in the 1-6 weeks postpartum window
Time frame: 1-6 weeks postpartum
Severe Composite Maternal Morbidity
Number of participants with any of the following: ICU admission, HELLP syndrome, eclampsia, stroke, renal failure, pulmonary edema, cardiomyopathy or maternal death.
Time frame: 1-6 weeks postpartum
Adverse Events
Allergic reactions (anaphylaxis, angioedema, skin rashes including Stevens Johnson and Toxic Epidermal necrolysis)
Time frame: 1-6 weeks Postpartum
Use of Resources
Number of participants that had additional Hospital Stay, Postpartum Clinic or Emergency room visit, Need for Imaging or other Invasive Procedures within 4-6 weeks of delivery, 4-6 weeks postpartum.
Time frame: 1-6 weeks postpartum
| Milestone | Hydrochlorothiazide 50mg Tablet | Placebo Tablet |
|---|---|---|
| Started | 201 | 199 |
| Completed | 196 | 196 |
| Not completed | 5 | 3 |
Any participants who had a visit to the hospital during the 1-6 weeks postpartum.
| Participants | Hydrochlorothiazide 50mg Tablet | Placebo Tablet |
|---|---|---|
| Number of Participants Required Re-Admission or Triage Visit | 3 | 10 |
Number of participants requiring additional antihypertensive agents in 1-6 weeks postpartum window
| Participants | Hydrochlorothiazide 50mg Tablet | Placebo Tablet |
|---|---|---|
| Number of Participants That Need Additional Antihypertensive Therapy | 6 | 6 |
Days that participants required to be in-house in the postpartum period
| days | Hydrochlorothiazide 50mg Tablet | Placebo Tablet |
|---|---|---|
| Length of Hospital Stay | 2.25 ± 0.93 | 2.18 ± 0.57 |
Number of participants that receive one additional doses in the 1-6 weeks postpartum
| Participants | Hydrochlorothiazide 50mg Tablet | Placebo Tablet |
|---|---|---|
| Total Additional Doses of Anti-hypertensive Therapy | 6 | 6 |
Number of participants that have a blood pressure greater than 150/90 in the 1-6 weeks postpartum window
| Participants | Hydrochlorothiazide 50mg Tablet | Placebo Tablet |
|---|---|---|
| Elevation of Blood Pressure >150/90 | 21 | 15 |
Number of participants with any of the following: ICU admission, HELLP syndrome, eclampsia, stroke, renal failure, pulmonary edema, cardiomyopathy or maternal death.
| Participants | Hydrochlorothiazide 50mg Tablet | Placebo Tablet |
|---|---|---|
| ICU admission | 0 | 0 |
| HELLP syndrome | 0 | 0 |
| Eclampsia | 0 | 0 |
| Maternal Death | 0 | 0 |
| Cardiomyopathy | 0 | 0 |
| Pulmonary edema | 0 | 0 |
| Renal failure | 0 | 0 |
| Stroke | 0 | 0 |
Allergic reactions (anaphylaxis, angioedema, skin rashes including Stevens Johnson and Toxic Epidermal necrolysis)
| Participants | Hydrochlorothiazide 50mg Tablet | Placebo Tablet |
|---|---|---|
| Anaphylaxis | 0 | 0 |
| Angioedema | 0 | 0 |
| Skin Rashes Including Stevens Johnson | 0 | 0 |
| Skin Rashes Including Toxic Epidermal Necrolysis | 0 | 0 |
Number of participants that had additional Hospital Stay, Postpartum Clinic or Emergency room visit, Need for Imaging or other Invasive Procedures within 4-6 weeks of delivery, 4-6 weeks postpartum.
| Participants | Hydrochlorothiazide 50mg Tablet | Placebo Tablet |
|---|---|---|
| Additional Hospital Stay | 1 | 0 |
| Clinic or Emergency room visit | 0 | 0 |
| Need for Imaging | 0 | 0 |
| Need for other Invasive Procedures | 0 | 0 |
Collected over 1-6 weeks postpartum. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Hydrochlorothiazide 50mg Tablet | 0/196 (0%) | 1/196 (0.5%) | 1/196 (0.5%) |
| Placebo Tablet | 0/196 (0%) | 0/196 (0%) | 1/196 (0.5%) |
| Event | Hydrochlorothiazide 50mg Tablet | Placebo Tablet |
|---|---|---|
| Hospital AdmissionGastrointestinal disorders | 1/196 | 0/196 |
| Event | Hydrochlorothiazide 50mg Tablet | Placebo Tablet |
|---|---|---|
| Patient diagnosed with Pyelonephritis and urosepsisRenal and urinary disorders | 1/196 | 0/196 |
| Allergic ReactionImmune system disorders | 0/196 | 1/196 |
| Age, Categorical(Participants) | Hydrochlorothiazide 50mg Tablet | Placebo Tablet | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 201 | 199 | 400 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Hydrochlorothiazide 50mg Tablet | Placebo Tablet | Total |
|---|---|---|---|
| Female | 201 | 199 | 400 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Hydrochlorothiazide 50mg Tablet | Placebo Tablet | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 3 | 4 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 30 | 21 | 51 |
| White | 168 | 175 | 343 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Hydrochlorothiazide 50mg Tablet | Placebo Tablet | Total |
|---|---|---|---|
| United States | 201 | 199 | 400 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2017 to primary completion in Apr 2025, 89 months.
Results were first posted in Jun 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hydrochlorothiazide
The University of Texas Medical Branch, Galveston →